samedan logo
 
 
spacer
home > pmps > summer 2019 > automated processes
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Automated Processes

Everyone’s been there − too many revision cycles and/or a poorly managed manual process that can result in labelling errors and cause delays, keeping you from getting that label or packaging artwork completed to deadline. These types of slowdowns and mistakes can be costly, particularly if they endanger patient safety, impede your delivery to market, or cause a supply chain disruption.

Unfortunately, without a standardised and automated process for users to leverage a source of truth and ensure consistent content and data, there is a lack of control and an omnipresent risk of error. This is why a highly configurable workflow engine is critical to track and manage labels and packaging artwork more effectively, from initial creation to final approval and publication. This is especially true in highly regulated verticals such as the pharmaceutical industry.

Unreliable Manual Processes

Cross-functional, manually-driven processes offer limited visibility and create huge inefficiencies. When it comes to labelling and artwork management, a labour-intensive approach involves too many steps, such as the routing of reviews and approvals via email. Also, spreadsheets and trackers can be overly complex in size and result in too much time spent sourcing, chasing, and trafficking. This makes collaboration increasingly difficult, and that means that critical mistakes can be made − especially when dealing with a full range of both internal and external stakeholders. To manage product packaging efficiently, you need an automated artwork approval process that can be incorporated into your product lifecycle and managed across your global enterprise. However, with all of this at stake, there are still many companies today using antiquated manual processes for artwork management. Inconsistent data, limited access to digital assets, poor visibility, reactive communications, and labourintensive, error-prone processes mean that teams working in operational silos spend an inordinate amount of time creating and editing artwork − then there’s the chaos that ensues when trying to determine which version is the most accurate, what step is next, and who is left to approve.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Paul Goldberg joined Loftware as the Founder of Gap Systems, having worked in the global packaging and technology sectors for over 20 years. At Gap Systems, Paul was responsible for global company leadership, product strategy, software design, strategic partnerships, and go-tomarket efforts. In 2007, Paul began to develop Smartflow from the ground up to help brands, retailers, and pharma organisations increase the efficiency of their product and packaging lifecycle processes. Since then, Paul has gained extensive industry expertise, working with clients such as AstraZeneca, Dermalogica, Kao Brands, Pharmavite, and Topco. Under Paul’s leadership, Gap Systems helped many world-leading brands, and retail and pharma organisations manage their packaging product lifecycles across 80 countries.
spacer
Paul Goldberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KKR Invests in Biosynth Carbosynth to Accelerate Growth and Help Build Global Life Sciences Tools Platform

London and Staad, 1 November 2021 – KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement